Related Experiment Video
Updated: Nov 2, 2025
An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient
Published on: November 30, 2022
Clinical Characteristics and Early Interventional Responses in Patients with Severe COVID-19 Pneumonia
Susu He1, Lina Fang2, Lingzhen Xia3
1Department of Respiratory Medicine, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang, China.
Insights
Early treatment with methylprednisolone and human immunoglobulin effectively improves outcomes for severe COVID-19 pneumonia patients. This combination therapy combats the uncontrolled inflammation causing acute respiratory distress syndrome (ARDS), a leading cause of death.
Area of Science:
- Infectious Diseases
- Pulmonology
- Critical Care Medicine
Background:
- Severe Coronavirus Disease-2019 (COVID-19) pneumonia can lead to progressive acute respiratory distress syndrome (ARDS), a primary cause of mortality.
- Uncontrolled inflammatory responses are central to the pathogenesis of severe COVID-19 pneumonia and ARDS.
- The emergence of COVID-19 has presented significant global health challenges, necessitating effective therapeutic strategies.
Purpose of the Study:
- To characterize the clinical, laboratory, and radiological features of severe COVID-19 pneumonia patients.
- To evaluate the efficacy of early combined treatment with methylprednisolone and human immunoglobulin in improving patient prognosis.
- To identify key diagnostic and intervention measures for enhancing clinical outcomes in severe COVID-19.
Main Methods:
- Retrospective analysis of 37 hospitalized severe COVID-19 pneumonia patients.
- Collection of demographic, clinical, laboratory, imaging, treatment, and outcome data from electronic medical records.
- Focus on patients treated between January 17, 2020, and February 18, 2020.
Main Results:
- Common symptoms included fever (78%), dry cough (76%), dyspnea (24%), and fatigue (24%).
- Elevated serum interleukin (IL)-6 (95%) and IL-10 (51%) were observed.
- Chest CT scans showed bilateral pneumonia in 95% of patients; early combined methylprednisolone and human immunoglobulin therapy improved prognosis.
Conclusions:
- Progressive ARDS, driven by uncontrolled inflammation, is the main cause of death in severe COVID-19 pneumonia.
- Early intervention utilizing methylprednisolone and human immunoglobulin demonstrated high effectiveness in improving patient prognosis.
- This combined therapy offers a promising strategy for managing severe COVID-19 pneumonia and mitigating ARDS.
Abstract:
Progressive acute respiratory distress syndrome (ARDS) is the most lethal cause in patients with severe COVID-19 pneumonia due to uncontrolled inflammatory reaction, for which we found that early intervention of combined treatment with methylprednisolone and human immunoglobulin is a highly effective therapy to improve the prognosis of COVID-19-induced pneumonia patients. Objective. Herein, we have demonstrated the clinical manifestations, laboratory, and radiological characteristics of patients with severe Coronavirus Disease-2019 (COVID-19) pneumonia, as well as measures to ensure early diagnosis and intervention for improving clinical outcomes of COVID-19 patients. Summary Background Data. The COVID-19 is a new infection caused by a severe acute respiratory syndrome- (SARS-) like coronavirus that emerged in China in December 2019 and has claimed millions of lives. Methods. We included 37 severe COVID-19 pneumonia patients who were hospitalized at Taizhou Public Health Medical Center in Zhejiang province from January 17, 2020, to February 18, 2020. Demographic, clinical, and laboratory features; imaging characteristics; treatment history; and clinical outcomes of all patients were collected from electronic medical records. Results. The patients' mean age was 54 years (interquartile range, 43-64), with a slightly higher male preponderance (57%). The most common clinical features of COVID-19 pneumonia were fever (29 (78%)), dry cough (28 (76%)), dyspnea (9 (24%)), and fatigue (9 (24%)). Serum interleukin (IL)-6 and IL-10 were elevated in 35 (95%) and 19 (51%) patients, respectively. Chest computerized tomography scan revealed bilateral pneumonia in 35 (95%) patients. Early intervention with a combination of methylprednisolone and human immunoglobulin was highly effective in improving the prognosis of these patients. Conclusions. Progressive acute respiratory distress syndrome is the most common cause of death in patients with severe COVID-19 pneumonia owing to an uncontrolled inflammatory response. Early intervention with methylprednisolone and human immunoglobulin was highly effective in improving their prognosis.
More Related Videos
09:36Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
08:05Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia
Published on: December 19, 2020
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia III: Complications and Assessment
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:21Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
01:30Acute Respiratory Failure-III
01:28Acute Coronary Syndrome IV: Interprofessional Care